Key result
Low-dose aspirin with or without atorvastatin is well tolerated in ICH survivors.
Why the study?
Practice guidelines equivocate on whether antiplatelet therapies or statins should be prescribed after spontaneous ICH due to an uncertain risk-benefit ratio.
Does aspirin and/or atorvastatin improve safety and tolerability without raising recurrent ICH risk in recent intracerebral hemorrhage survivors?
RCT (n=62)
No
Does aspirin and/or atorvastatin improve safety and tolerability without raising recurrent ICH risk in recent intracerebral hemorrhage survivors?
Low-dose aspirin with or without atorvastatin appears safe and well-tolerated for secondary prevention in recent intracerebral hemorrhage survivors, supporting the feasibility of a larger definitive trial.
Answers are grounded in this paper and cite their sources.
Supports aspirin ± atorvastatin for secondary prevention in recent ICH survivors; extends feasibility for larger efficacy trials.
• ICH survivors are at high risk of ischemic vascular events. • Guidelines equivocate on the role of statins and/or antiplatelets after ICH due to uncertain risk-benefit ratio. • This pilot trial assessed safety and tolerability of aspirin and/or atorvastatin among recent Ghanaian ICH survivors. • We found aspirin and/or atorvastatin may not raise risk of recurrent ICH. • A definitive, larger RCT study is warranted. Intracerebral hemorrhage (ICH) survivors are at high risk for future ischemic vascular events and recurrent ICH. Due to an uncertain risk-benefit ratio, practice guidelines equivocate on whether antiplatelet therapies or statins should be prescribed for secondary prevention in the aftermath of a spontaneous ICH. To preliminarily assess the tolerability and safety of low dose aspirin with or without atorvastatin at low and high doses for secondary prevention after ICH. In this single-center feasibility trial in Ghana, participants were randomized to 1 of 6 arms: no aspirin (ASA-0) + no atorvastatin (ATO-0) n=10); aspirin 75mg + no atorvastatin (ASA-75 + ATO-0, n=10); no aspirin + atorvastatin 20 mg (ASA-0 + ATO-20, n=10); no aspirin + atorvastatin 80 mg (ASA-0 + ATO-80, n=10); aspirin 75mg + atorvastatin 20 mg (ASA-75 + ATORVA-20, n=11); and aspirin 75mg + atorvastatin 80mg (ASA-75 + ATORVA 80, n=11) taken daily for 12 months. All participants received standard of care secondary prevention comprising of antihypertensive medications for blood pressure control. Outcomes assessed included major adverse cardiovascular events (stroke, myocardial infarction, vascular death), treatment-limiting side effects, change in Modified Rankin score and global cognition. We enrolled 62 eligible recent ICH survivors between January 24, 2021, and March 16, 2022, mean (SD) age of 53 (11.6) years, 30 (48%) were males. There were 3 deaths, one in each of these arms: ASA-0 + ATO-0; ASA-0 + ATO-20; ASA-0 + ATO-80. There was one non-fatal, ischemic stroke in the ASA-75 + ATO-80 arm and one non-fatal ICH in the ASA-75 + ATO-20 arm. No treatment limiting side effects were recorded. These feasibility and preliminary data suggest that aspirin with or without atorvastatin up to one year after a spontaneous ICH is well tolerated and may not raise recurrent ICH risk. A definitive large study with longer term follow-up is warranted.
No takes yet. Share an insight, caveat, or question.
Sarfo et al. (2025) conducted an RCT in Intracerebral hemorrhage (ICH) (n=62). Aspirin with or without atorvastatin vs. No aspirin and no atorvastatin was evaluated on Major adverse cardiovascular events, treatment-limiting side effects, change in Modified Rankin score and global cognition. Low-dose aspirin with or without atorvastatin was well tolerated over 12 months among 62 intracerebral hemorrhage survivors, with no treatment-limiting side effects recorded.
Synapse has enriched 10 related papers. Consider them for comparative context: